论文部分内容阅读
目的:通过回顾性分析87例非小细胞肺癌(NSCLC)的临床病理资料,探索survivin、p53和Bcl-2的临床病理相关性以及联合检测提示NSCLC预后的可能性。方法:采用免疫组化SP法检测NSCLC中survivin、p53和Bcl-2的表达。用Spearman等级相关系数检验其与NSCLC发生的相关性。结果:NSCLC组织的survivin蛋白阳性表达率为55.2%(48/87),阳性表达主要定位于NSCLC细胞质中。不同分期的NSCLC在survivin阳性表达率方面存在显著差异:III和IV期(中晚期)病例阳性率为71.1%(32/45),而I和II期(早中期)阳性率则为38.1%(16/42,P<0.01)。不同原发肿瘤分期病例未显示出差异性survivin表达;而survivin表达则具有显著N分期相关性,无淋巴结转移(N0)病例的阳性率为43.5%(27/62),有淋巴结转移(N1和N2)病例则为84.0%(21/25,P<0.01)。Survivin在鳞癌和腺癌中表达率分别为76.0%(38/50)和27.0%(10/37),其表达在两种病理类型间存在统计学差异(P<0.01)。NSCLC组织的p53蛋白阳性表达率为64.6%(56/87),阳性表达产物主要定位于NSCLC细胞质中。有淋巴结转移(N1和N2)病例阳性率(84.0%,21/25)显著高于无淋巴结转移病例(54.8%)(34/62,P<0.01)。而且p53表达同时还具有组织类型相关性,鳞癌病例阳性率(76.0%,38/50)显著高于腺癌病例(27.0%)(10/37,P<0.01)。NSCLC组织的Bcl-2蛋白阳性表达率为56.3%(49/87),阳性表达产物定位于NSCLC细胞质和细胞核中。有淋巴结转移(N1-2)病例阳性率(48.0%,12/25)明显高于无淋巴结转移病例(22.6%)(14/62,P<0.01)。结论:Survivin上调显示出与NSCLC的临床病理相关性,同时survivin与p53和Bcl-2在NSCLC中也具有一定的临床病理相关性。
OBJECTIVE: To explore the clinicopathological correlation of survivin, p53 and Bcl-2 and to explore the possibility of prognosis of NSCLC by retrospective analysis of clinicopathological data of 87 cases of non-small cell lung cancer (NSCLC). Methods: The expressions of survivin, p53 and Bcl-2 in NSCLC were detected by immunohistochemical SP method. Correlation with NSCLC was tested by Spearman’s rank correlation coefficient. Results: The positive rate of survivin protein in NSCLC tissues was 55.2% (48/87). The positive expression of survivin protein mainly localized in the cytoplasm of NSCLC. The positive rates of survivin expression in different stages of NSCLC were significantly different: the positive rates of stage III and IV were 71.1% (32/45), while the positive rates of stage I and II (early and middle stage) were 38.1% ( 16/42, P <0.01). There was no significant difference in the expression of survivin between different primary tumor staging cases, while the expression of survivin was significantly correlated with stage N (43.5% (27/62), with lymph node metastasis (N1 and N2 ) Cases were 84.0% (21/25, P <0.01). The positive rates of Survivin in squamous cell carcinoma and adenocarcinoma were 76.0% (38/50) and 27.0% (10/37), respectively. There was a significant difference in the expression of Survivin between the two pathological types (P <0.01). The positive expression rate of p53 protein in NSCLC tissues was 64.6% (56/87), and the positive expression products mainly localized in the cytoplasm of NSCLC. The positive rates of lymph node metastasis (N1 and N2) were significantly higher than those without lymph node metastasis (84.8%, 84/21) (34/62, P <0.01). In addition, the positive expression rates of p53 and p53 were significantly higher in patients with squamous cell carcinoma (76.0%, 38/50) than in adenocarcinoma (27.0%, P <0.01). The positive expression rate of Bcl-2 protein in NSCLC tissues was 56.3% (49/87). The positive expression products were located in the cytoplasm and nucleus of NSCLC. The positive rate of lymph node metastasis (N1-2) was significantly higher than that of non-lymph node metastasis (22.6%) (48.0%, 12/25) (14/62, P <0.01). Conclusion: Survivin upregulation shows clinicopathological correlation with NSCLC. Survivin also has a clinicopathological correlation with p53 and Bcl-2 in NSCLC.